GlassScriptPhysician profile
Nicholas Christian Risbrudt
NPI 1275193864
$3,539.96
in general payments reported to CMS, 2019-2025
28 companies · $808 in 2025
The $808 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.95 · 2020: $31.11 · 2021: $671 · 2022: $568 · 2023: $572 · 2024: $793 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $687.23 | 2021-2025 | Acthar |
| Abbvie INC. | $681.32 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Alcon Vision LLC | $451.93 | 2020-2025 | Clareon, Argos, Hydrus Microstent |
| Glaukos Corporation | $245.95 | 2022-2025 | Photrexa Viscous and Photrexa, Idosetr, Ce-Marked Kxla System |
| Tarsus Pharmaceuticals, INC. | $228.09 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $160.63 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $123.44 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $120.34 | 2022-2025 | Oxervate |
| Amgen INC. | $86.61 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $75.04 | 2021-2024 | Omni Surgical System |
| Allergan, INC. | $73.79 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $69.25 | 2021-2023 | |
| Aerie Pharmaceuticals, INC. | $67.80 | 2019-2021 | |
| Horizon Therapeutics Plc | $61.18 | 2022-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $58.35 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $50.00 | 2021 | |
| Harrow Eye, LLC | $44.97 | 2024-2025 | Vevye |
| Rxsight INC | $44.57 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $35.83 | 2025 | Xiidra, Miebo |
| The Cameron-Ehlen Group, INC. | $30.75 | 2019-2023 | Tecnis Iol, Healon Pro, Tecnis Simplicity |
| Biotissue Holdings INC. | $28.81 | 2022-2024 | |
| New World Medical,INC. | $22.80 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $20.53 | 2023 | Syfovre |
| Johnson & Johnson Vision Care, INC. | $19.18 | 2022 | |
| Rayner Intraocular Lenses Limited | $18.50 | 2025 | Omidria |
| Johnson & Johnson Surgical Vision, INC. | $16.24 | 2024 | Tecnis Iol |
| Omeros Corporation | $11.86 | 2019 | |
| Lkc Technologies, INC. | $4.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Risbrudt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.